Claryn Mechanism of Action

Pharmacology: Pharmacodynamics: Granules for suspension: Clarithromycin is a macrolide antibiotic whose spectrum of activity includes many gram-positive (Staphylococcus aureus, S. pneumonia, and S. pyogenes) and gram-negative aerobic bacteria (Haemophilus influenzae, H. parainfluenzae, and Moraxella catarrhalis), many anaerobic bacteria, some mycobacteria, and some other organism including Mycoplasma, Ureaplasma, Chlamydia, Toxoplasma, and Borrelia. Other aerobic bacteria that clarithromycin has activity against include C. pneumoniae and M. pneumoniae, Clarithromycin has an in-vitro activity that is similar or greater than that of erythromycin against erythromycin-susceptible organisms. Clarithromycin is usually bacteriostatic, but may be bactericidal depending on the organism and the drug concentration.
Pharmacokinetics: Film-coated tablet: Clarithromycin is rapidly absorbed from the gastrointestinal tract following oral administration, and undergoes first-pass metabolism; the bioavailability of the parent drug is about 55%. The extent of absorption is relatively unaffected by the presence of food. Peak concentrations of clarithromycin and its principal active metabolite 14-hydroxyclarithromycin are reported to be about 600 and 700 nanograms per mL respectively following a single 250-mg dose by mouth; at steady state the same dose given every 12 hours as tablets produces peak concentrations of clarithromycin of about 1 μg per mL. The same dose given as suspension produces a steady-state plasma concentration of about 2 μg per mL.
The pharmacokinetics of clarithromycin are non-linear and dose dependent; high doses may produce disproportionate increases in peak concentration of the parent drug, due to saturation of the metabolite pathways.
Granules for suspension: Clarithromycin is rapidly absorbed from the gastrointestinal tract and undergoes first-pass metabolism; the bioavailability of the parent drug is about 55%. The extent of absorption is relatively unaffected by the presence of food. Peak plasma concentrations occur 2 to 3 hours after an oral dose. At steady state, peak plasma concentrations of clarithromycin, and its principal active metabolite, 14-hydroxyclarithromycin, are about 1 and 0.6 microgram/mL, respectively, after 250 mg orally every 12 hours as tablets. The same dose given as a suspension to fasting subjects produces steady-state plasma concentrations of about 2 micrograms/mL of clarithromycin and about 0.7 microgram/mL of 14-hydroxyclarithromycin. Steady-state concentrations are reached within 3 to 4 days. The pharmacokinetics of clarithromycin are non-linear and dose dependent; high closes may produce disproportionate increases in peak concentrations of the parent drug, due to saturation of the metabolite pathways. However, the non-linearity is slight at the recommended doses of 250 to 500 mg every 8 to 12 hours.